STRATEGIC FOCUS

Since 2004, the U.S. Centers for Disease Control and Prevention (CDC) in Kenya, through the U.S. President's Emergency Plan for AIDS Relief (PEPFAR), has worked with multiple stakeholders, including the Kenya Ministry of Health (MOH), local, and international partners to support and strengthen prevention and control efforts of the HIV and tuberculosis (TB) epidemics. To achieve these goals, CDC is:

- Developing strategic policy guidelines, national HIV surveillance, and strategic information systems, enabling early adoption of new scientific evidence and data use.
- Improving service delivery in HIV and TB prevention, identification, linkage, treatment, and retention of people living with HIV (PLHIV) or TB.
- Implementing high-quality laboratory services, strengthening health systems, and establishing close partnerships with national and county governments to enhance the sustainability of programs.
- Establishing and maintaining sound financial management systems to ensure transparency, • accountability, and compliance with required regulations.

KEY ACTIVITIES AND ACCOMPLISHMENTS

Through the support of CDC and its partners, from October 2021 through September 2022, PEPFAR program outcomes in the following areas were achieved:

Comprehensive HIV Treatment:

- Provision of antiretroviral therapy (ART) to 781,716 PLHIV, including 33,411 children below 15 years.
- 95 percent of all PLHIV on treatment have an undetectable HIV viral load (VL).
- Elimination of Mother-to-Child Transmission:
- 330,044 pregnant women enrolled in antenatal care know their HIV status (99 percent), and of those testing HIV-positive, 99 percent are on HIV treatment, enabling babies to be born HIV-free.

HIV Prevention:

- 36,394 men were medically circumcised through VMMC to prevent acquiring HIV.
- 59,574 individuals received pre-exposure prophylaxis (PrEP).
- 232,025 adolescent girls and young women received prevention interventions.
- 278,532 individuals in vulnerable populations received free health services.
- 1.5 million Kenyans were tested for HIV, and those negative were linked to HIV prevention resources. TB/HIV:
- CDC continues to provide TB preventive treatment (TPT) to PLHIV on ART focusing on scaling up shorter regimens. 96 percent of identified HIV/TB patients in CDC-supported sites received ART while on TB treatment.
- CDC supported the MOH in developing the 2023-2028 TB, Leprosy, and Lung Health Strategic Plan.

Laboratory and Health Systems Strengthening:

- 89 labs received international accreditation over the past fifteen years, contributing to 1.2 million HIV VL tests, 900,000 TB tests, and 11 million HIV diagnostic tests per year.
- Proficiency panels provided to 21,000 staff for HIV/TB testing, 65 VL/Early Infant Diagnosis labs, and over 2,000 TB labs, including 202 GeneXpert, implemented continuous quality improvement activities in 3,857 rapid HIV testing sites.
- Set up a national laboratory equipment calibration/servicing center and biosafety cabinet certification to improve the quality of testing health worker safety.
- Provide continued technical support for laboratory-based surveillance and surveys, including SARS_CoV-2 surveillance in PLHIV, recency surveillance, HIV drug resistance, and the Kenya Populationbased HIV Impact Assessment.
- Conducted country readiness assessments and developed memoranda of understanding between CDC and counties for phased transition of HIV and TB services. Established 12 government-to-government (G2G) cooperative agreements with counties.

Science, Surveillance, and Strategic Information:

- 92 percent of patients on treatment have an electronic medical record for more efficient tracking.
- CDC leads the incorporation of the unique national identifier in the electronic systems facilitating tracking of HIV service provision longitudinally across facilities.
- CDC leverages existing rich individual-level data to roll out site-level implementation of machine learning to improve patient outcomes.
- With support from CDC, Kenya's comprehensive HIV surveillance programs continue to increase coverage of case-based surveillance, recent HIV infection, mortality, and drug resistance surveillance.
- In partnership with CDC, Kenya is investing in a key population biobehavioral survey in nine highpriority counties to facilitate effective program planning and resource allocation for epidemic control and a national population-based HIV impact assessment to obtain the current status of the epidemic.



Our success is built on the backbone of science and strong partnerships.

Country Quick Facts (worldbank.org/en/wherewe-work)

Population (millions): 54.02 (2022)

Under 5 Mortality: 37.2/1,000 live births (2021)

Life Expectancy: 61.4 years (2021)

Global HIV/AIDS Epidemic (aidsinfo.unaids.org)

Estimated HIV Prevalence (Ages 15-49): 3.7% (2022)

Estimated AIDS Deaths (Age ≥15): 16,000 (2022)

Estimated Orphans Due to AIDS: 590,000 (2022)

Reported Number Receiving Antiretroviral Therapy (ART) (Age ≥15): 1,240,454 (2022)

Global Tuberculosis (TB) Epidemic (who.int/tb/country/data/ profiles/en)

Estimated TB Incidence: 251/100,000 population (2021)

TB Patients with Known HIV Status who are HIV-Positive: 24% (2021)

TB Treatment Success Rate: 85% (2020)

DGHT Country Staff: 63 Locally Employed Staff: 56 Direct Hires: 7 Fellows & Contractors: 0



September 2023 | The CDC Division of Global HIV & TB activities are implemented as part of the U.S. President's Emergency Plan for AIDS Relief (PEPFAR); non-HIV related TB activities are supported by non-PEPFAR funding

Key Country Leadership

President[.] William Ruto

Cabinet Secretary for Health: Susan Nakhumicha Wafula

U.S. Ambassador:

CDC Country Director: Amy

DGHT Program Director: Jennifer Galbraith

Per Capita GNI: \$2,170 (2022)

Meg Whitman

Herman-Roloff